Clinical Trials Logo
  1. Home
  2. Sjogren's Syndrome
  3. NCT06104124

A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

Sjogren's Syndrome Clinical Trial

Official title:
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome With Moderate-to-severe Systemic Disease Activity

Clinical Trial Summary

Primary Objective: To evaluate the effect of dazodalibep on systemic manifestations of Sjögren's Syndrome (SS) in participants with moderate-to-severe systemic disease activity. Secondary Objectives: 1. To evaluate the effect of dazodalibep on patient reported outcomes (PROs) in participants with SS. 2. To evaluate the safety and tolerability of dazodalibep in participants with SS

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06104124
Study type Interventional
Source Horizon Pharma Ireland, Ltd., Dublin Ireland
Contact Study Director
Phone 1-866-479-6742
Email clinicaltrials@horizontherapeutics.com
Status Recruiting
Phase Phase 3
Start date October 26, 2023
Completion date May 8, 2026
View Details
See also
  Status Clinical Trial Phase
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT04968912 - A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS) Phase 2
Completed NCT03203382 - Corneal Nerve Structure in Sjogren's
Completed NCT00809003 - Assessment of Inflammatory and Functional Changes in the Ocular Surface Associated With Dry Eye Disease N/A
Completed NCT00023491 - Potential of Transplanted Stem Cells to Mature Into Salivary Gland and Cheek Cells N/A
Completed NCT05005806 - Fish Oil (Omega 3 ) in Sjogren's Syndrome Phase 2/Phase 3
Enrolling by invitation NCT03436576 - Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye Phase 3
Terminated NCT04143841 - Viveye Ocular Magnetic Neurostimulation System (OMNS) for the Management of Severe Dry Eye Disease N/A
Completed NCT03611283 - Topical Management of Xerostomia With Dry Mouth Products N/A
Recruiting NCT05115487 - Evaluation of Hand Functions in Newly Diagnosed Primary Sjögren's Syndrome
Recruiting NCT05383677 - Anifrolumab Treatment for 24 Weeks in Patients With Primary Sjögren's Syndrome Phase 2
Not yet recruiting NCT03938207 - Dry Eye Syndrome, Healthy Control, Sjögren's Syndrome and Other Inflammation Disease in Taiwan Biobank
Completed NCT04239521 - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Completed NCT04546542 - Hydroxychloroquine Blood Levels in Primary Sjögren Syndrome Patients
Recruiting NCT05085431 - A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome Early Phase 1
Completed NCT00565526 - Evaluation of the Role of the Autonomic Nervous System in Sj(SqrRoot)(Delta)Gren s Syndrome
Completed NCT01369589 - An Evaluation of the Impact of a Single Dose of P-552 on Oral Mucosal Wetness Phase 1/Phase 2
Completed NCT00001953 - The Functioning of Immune and Hormonal Systems in Patients With Sjogren's Syndrome and in Healthy Volunteers N/A
Completed NCT00001731 - Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops Phase 2
Recruiting NCT03953703 - Levocarnitine for Dry Eye in Sjogren's Syndrome Phase 2